Enzyme ablation of the hyperplastic prostate may be an ideal method of management of BPH. However, the unsatisfactory ablation affects in vivo contrast with successful in vitro results limiting the ...

doctors in surgery, AUA 2017, prostate biopsy, surgeons, emergency room, doctor and asisstant In a study, 81.1% of men were able to void after an average of 28 days after treatment. The following ...

Investigators reported an 88% early treatment success rate in 52 men who underwent MRI-guided transurethral ultrasound ablation for localized prostate cancer. Customized prostate ablation with ...

Prostate cancer may soon be treated more effectively using ultrasound at therapeutic levels, without the significant and distressing side effects of more traditional treatments. A new study presented ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...

In patients presenting with clinically localized prostate cancer, the risk of biochemical failure increases significantly with higher Gleason scores, prostate specific antigen (PSA) levels, and ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Pursuant to an agreement entered into with Knight in April 2015, Knight had acted as Profound’s exclusive distributor for the technology in Canada. Profound has now regained the Canadian TULSA-PRO ...

TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Medicare Part B covers Aquablation for BPH if a person meets specific eligibility criteria, including a prostate volume of 30 to 150 cubic centimeters (cc). Medicare does not cover Aquablation in ...